
Processa Pharmaceuticals buys Vidya Therapeutics
Processa Pharmaceuticals has acquired Vidya Therapeutics, a clinical-stage biotechnology company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases. The product is initially focused on potentially best-in-class BTK inhibition in food allergy, chronic spontaneous urticaria (CSU) and relapsing multiple sclerosis (RMS). Concurrent with the acquisition, Processa entered… Read More
